C Chakiba1, P Lagarde2, D Pissaloux3, A Neuville2, C Brulard4, G Pérot5, J M Coindre2, P Terrier6, D Ranchere-Vince3, A Ferrari7, P Collini8, A J H Suurmeijer9, J Y Blay10, S A Terrisse11, S Piperno-Neumann12, G Averous13, B Bui14, D Orbach15, A Italiano14, F Chibon16. 1. Department of Medical Oncology, Institut Bergonié; Université Victor Segalen Bordeaux 2; Institut National de la Santé et de la Recherche Medicale (INSERM), U916-Institut Bergonié. 2. Université Victor Segalen Bordeaux 2; Institut National de la Santé et de la Recherche Medicale (INSERM), U916-Institut Bergonié; Department of Pathology, Institut Bergonié, Bordeaux. 3. Department of Pathology, Centre Léon Bérard, Lyon. 4. Institut National de la Santé et de la Recherche Medicale (INSERM), U916-Institut Bergonié. 5. Institut National de la Santé et de la Recherche Medicale (INSERM), U916-Institut Bergonié; Department of Pathology, Institut Bergonié, Bordeaux. 6. Department of Pathology, Institut Gustave Roussy, Villejuif, France. 7. Department of Medical Oncology. 8. Department of Pathology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy. 9. Department of Pathology, University of Groningen University Medical Center, Groningen, The Netherlands. 10. Department of Medical Oncology, Centre Léon Berard, Lyon. 11. Department of Medical Oncology, Institut Gustave Roussy, Villejuif. 12. Department of Medical Oncology, Institut Curie, Paris. 13. Department of Pathology, Centre Hospitalier Universitaire Hautepierre, Strasbourg. 14. Department of Medical Oncology, Institut Bergonié; Institut National de la Santé et de la Recherche Medicale (INSERM), U916-Institut Bergonié. 15. Department of Pediatric Oncoloy, Institut Curie, Paris, France. 16. Institut National de la Santé et de la Recherche Medicale (INSERM), U916-Institut Bergonié; Department of Pathology, Institut Bergonié, Bordeaux. Electronic address: f.chibon@bordeaux.unicancer.fr.
Abstract
BACKGROUND: Synovial sarcoma (SS) is an aggressive soft-tissue tumor. Despite being considered as a chemosensitive disease, the real impact of perioperative chemotherapy on metastasis-free survival (MFS) is controversial. We have shown that metastatic relapse of SS is strongly associated with genomic complexity. There are no data regarding the potential correlation between genomic complexity and response to chemotherapy. PATIENTS AND METHODS: The study population included 65 SS patients diagnosed between 1991 and 2013 and with available tissue material. Genomic profiling was carried out by using array-CGH. Forty-five SS out of the 65 patients were treated with neoadjuvant anthracycline/ifosfamide-based chemotherapy. Radiological response was assessed according to RECIST criteria. Histological response was defined by the percentage of recognizable tumor cells on the surgical specimen. RESULTS: Genomic complexity was significantly associated with MFS. However, there was no statistically significant association between radiological or histological response and genomic complexity. CONCLUSION: The absence of significant association between response to chemotherapy and genomic complexity suggests that the prognostic value of chromosome instability in SS is independent of response to chemotherapy; mechanisms leading to metastatic relapse of SS are intrinsic to the biology of the tumor and current cytotoxic drugs are only poorly efficient to prevent it.
BACKGROUND:Synovial sarcoma (SS) is an aggressive soft-tissue tumor. Despite being considered as a chemosensitive disease, the real impact of perioperative chemotherapy on metastasis-free survival (MFS) is controversial. We have shown that metastatic relapse of SS is strongly associated with genomic complexity. There are no data regarding the potential correlation between genomic complexity and response to chemotherapy. PATIENTS AND METHODS: The study population included 65 SS patients diagnosed between 1991 and 2013 and with available tissue material. Genomic profiling was carried out by using array-CGH. Forty-five SS out of the 65 patients were treated with neoadjuvant anthracycline/ifosfamide-based chemotherapy. Radiological response was assessed according to RECIST criteria. Histological response was defined by the percentage of recognizable tumor cells on the surgical specimen. RESULTS: Genomic complexity was significantly associated with MFS. However, there was no statistically significant association between radiological or histological response and genomic complexity. CONCLUSION: The absence of significant association between response to chemotherapy and genomic complexity suggests that the prognostic value of chromosome instability in SS is independent of response to chemotherapy; mechanisms leading to metastatic relapse of SS are intrinsic to the biology of the tumor and current cytotoxic drugs are only poorly efficient to prevent it.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Galen Hostetter; Su Young Kim; Stephanie Savage; Gerald C Gooden; Michael Barrett; Jian Zhang; Lalitamba Alla; April Watanabe; Janine Einspahr; Anil Prasad; Brian J Nickoloff; John Carpten; Jeffrey Trent; David Alberts; Michael Bittner Journal: Nucleic Acids Res Date: 2009-10-29 Impact factor: 16.971
Authors: A Italiano; N Penel; Y-M Robin; B Bui; A Le Cesne; S Piperno-Neumann; M Tubiana-Hulin; E Bompas; C Chevreau; N Isambert; S Leyvraz; P P du Chatelard; A Thyss; J-M Coindre; J-Y Blay Journal: Ann Oncol Date: 2008-12-16 Impact factor: 32.976
Authors: Daniel Orbach; Véronique Mosseri; Daniel Pissaloux; Gaelle Pierron; Bernadette Brennan; Andrea Ferrari; Frederic Chibon; Gianni Bisogno; Gian Luca De Salvo; Camille Chakiba; Nadège Corradini; Véronique Minard-Colin; Anna Kelsey; Dominique Ranchère-Vince Journal: Cancer Med Date: 2018-03-13 Impact factor: 4.452
Authors: Myrella Vlenterie; Melissa H S Hillebrandt-Roeffen; Uta E Flucke; Patricia J T A Groenen; Bastiaan B J Tops; Eveline J Kamping; Rolph Pfundt; Diederik R H de Bruijn; Ad H M Geurts van Kessel; Han J H J M van Krieken; Winette T A van der Graaf; Yvonne M H Versleijen-Jonkers Journal: Oncotarget Date: 2015-10-27